AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

The drugmaker has invested $10 billion in Wake and Durham counties over the past 30 years. Biogen says that figure will ...

President Donald Trump is keeping up the pace with seemingly a new tariff development every day. This time, he flagged that ...

Finally, don't discount legal challenges to the president's tariffs. An argument could be made that pharmaceutical products ...

W hen Donald Trump’s tariffs are mentioned, you might recall his “Liberation Day” duties on uninhabited islands, his on-again ...

Johnson and Johnson beat Wall Street’s quarterly sales expectations and raised its full-year outlook, a show of confidence as ...

President Trump announced potential tariffs on imported pharmaceuticals by month's end, followed by semiconductor levies.

The opening salvo of second-quarter earnings calls this week came against President Donald Trump’s renewed calls for a tariff ...

Despite the threat of a 200% tariff, most pharma stocks remained stable. US President Donald Trump’s 200% tariff threat on the pharmaceutical industry is a “shock” that will reverberate through global ...

Drugmaker Swedish Orphan Biovitrum AB’s Chief Executive Officer Guido Oelkers said he doesn’t think tariff threats on the ...